AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.
Crown, J.; O'Leary, M. The taxanes: An update. Lancet 2000, 355, 1176–1178.
Yared, J. A.; Tkaczuk, K. H. R. Update on taxane development: New analogs and new formulations. Drug Des. Devel. Ther. 2012, 6, 371–384.
Zhao, P. X.; Astruc, D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem 2012, 7, 952–972.
Zhang, Z. P.; Mei, L.; Feng, S. S. Paclitaxel drug delivery systems. Expert Opin. Drug Deliv. 2013, 10, 325–340.
Paller, C. J.; Antonarakis, E. S. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 2011, 5, 117–124.
Kartner, N.; Riordan, J. R.; Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221, 1285–1288.
Vrignaud, P.; Sémiond, D.; Lejeune, P.; Bouchard, H.; Calvet, L.; Combeau, C.; Riou, J. F.; Commerçon, A.; Lavelle, F.; Bissery, M. C. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 2013, 19, 2973–2983.
De Bono, J. S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J. P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M. J.; Shen, L. J. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010, 376, 1147–1154.
Cragg, G. M. Paclitaxel (Taxol®): A success story with valuable lessons for natural product drug discovery and development. Med. Res. Rev. 1998, 18, 315–331.
Cragg, G. M.; Newman, D. J. A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 2004, 67, 232–244.
Rowinsky, E. Paclitaxel pharmacology and other tumor types. Semin. Oncol. 1998, 24, S19-1–S19-12.
Rowinsky, M.; Eric, K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48, 353–374.
Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665–667.
MacConnachie, A. Docetaxel (Taxotere, Rhone-Poulenc Rorer). Intensive Crit. Care Nurs. 1997, 13, 119–120.
Guenard, D.; Gueritte-Voegelein, F.; Potier, P. Taxol and taxotere: Discovery, chemistry, and structure-activity relationships. Acc. Chem. Res. 1993, 26, 160–167.
Diaz, J. F.; Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32, 2747–2755.
Yusuf, R. Z.; Duan, Z.; Lamendola, D. E.; Penson, R. T.; Seiden, M. V. Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3, 1–19.
Jones, S. E.; Erban, J.; Overmoyer, B.; Budd, G. T.; Hutchins, L.; Lower, E.; Laufman, L.; Sundaram, S.; Urba, W. J.; Pritchard, K. I. et al. Randomized phase Ⅲ study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 2005, 23, 5542–5551.
Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S. B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter phase Ⅱ trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108, 241–250.
Untch, M.; Untch, A.; Sevin, B. U.; Angioli, R.; Perras, J. P.; Koechli, O.; Averette, H. E. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anti-Cancer Drugs 1994, 5, 24–30.
Valero, V.; Jones, S. E.; Von Hoff, D. D.; Booser, D. J.; Mennel, R. G.; Ravdin, P. M.; Holmes, F. A.; Rahman, Z.; Schottstaedt, M. W.; Erban, J. K. et al. A phase Ⅱ study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 1998, 16, 3362–3368.
Verschraegen, C. F.; Sittisomwong, T.; Kudelka, A. P.; de Paula Guedes, E.; Steger, M.; Nelson-Taylor, T.; Vincent, M.; Rogers, R.; Atkinson, E. N.; Kavanagh, J. J. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J. Clin. Oncol. 2000, 18, 2733–2739.
Horwitz, S. B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H. J.; Yang, C. P. Taxol: Mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr. 1993, 55–61.
Lockhart, A. C.; Tirona, R. G.; Kim, R. B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol. Cancer Ther. 2003, 2, 685–698.
Childs, S.; Yeh, R. L.; Hui, D.; Ling, V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 1998, 58, 4160–4167.
Hopper-Borge, E.; Chen, Z. S.; Shchaveleva, I.; Belinsky, M. G.; Kruh, G. D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res. 2004, 64, 4927–4930.
Bradshaw, D. M.; Arceci, R. J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 1998, 16, 3674–3690.
Fojo, T.; Menefee, M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann. Oncol. 2007, 18, v3–v8.
Perez, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther. 2009, 8, 2086– 2095.
Vrignaud, P.; Semiond, D.; Benning, V.; Beys, E.; Bouchard, H.; Gupta, S. Preclinical profile of cabazitaxel. Drug Des. Devel. Ther. 2014, 8, 1851–1867.
Bouchard, H.; Semiond, D.; Risse, M. L.; Vrignaud, P. Novel taxanes: Cabazitaxel case study. In Analogue-Based Drug Discovery Ⅲ; Fischer, J.; Ganellin, C. R.; Rotella, D. P., Eds.; Wiley-VCH: Weinheim, Germany, 2012; pp 319–341.
Paller, C. J.; Antonarakis, E. S. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 2011, 5, 117–124.
Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30.
De Bono, J. S.; Scher, H. I.; Montgomery, R. B.; Parker, C.; Miller, M. C.; Tissing, H.; Doyle, G. V.; Terstappen, L. W. W. M.; Pienta, K. J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14, 6302–6309.
Semenas, J.; Allegrucci, C.; A Boorjian, S. A.; Mongan, N. P.; Liao Persson, J. Overcoming drug resistance and treating advanced prostate cancer. Curr. Drug Targets 2012, 13, 1308–1323.
Pean, E.; Demolis, P.; Moreau, A.; Hemmings, R. J.; O'Connor, D.; Brown, D.; Shepard, T.; Abadie, E.; Pignatti, F. The European medicines agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: Summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2012, 17, 543–549.
Galsky, M. D.; Dritselis, A.; Kirkpatrick, P.; Oh, W. K. Cabazitaxel. Nat. Rev. Drug Discov. 2010, 9, 677–678.
Mahajan, M.; Kaur Khurana, R.; Shri Sahajpal, N.; Utreja, P.; Sankar, R.; Singh, B.; Kumar Jain, S. Emerging strategies and challenges for controlled delivery of taxanes: A comprehensive review. Curr. Drug Metab. 2015, 16, 453–473.
Swain, S. M.; Arezzo, J. C. Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin. Adv. Hematol. Oncol. 2008, 6, 455–467.
Krebs, A.; Goldie, K. N.; Hoenger, A. Structural rearrangements in tubulin following microtubule formation. EMBO Rep. 2005, 6, 227–232.
Downing, K. H.; Nogales, E. Crystallographic structure of tubulin: Implications for dynamics and drug binding. Cell Struct. Funct. 1999, 24, 269–275.
Abal, M.; Andreu, J.; Barasoain, I. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 2003, 3, 193–203.
Dı́az, J. F.; Valpuesta, J. M.; Chacón, P.; Diakun, G.; Andreu, J. M. Changes in microtubule protofilament number induced by taxol binding to an easily accessible site: Internal microtubule dynamics. J. Biol. Chem. 1998, 273, 33803–33810.
Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol. 2005, 6, 229–239.
Balasubramanian, S. V.; Alderfer, J. L.; Straubinger, R. M. Solvent- and concentration-dependent molecular interactions of taxol (paclitaxel). J. Pharm. Sci. 1994, 83, 1470–1476.
Balasubramanian, S. V.; Straubinger, R. M. Taxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranes. Biochemistry 1994, 33, 8941–8947.
Sharma, A.; Straubinger, R. M. Novel taxol formulations: Preparation and characterization of taxol-containing liposomes. Pharm. Res. 1994, 11, 889–896.
Campbell, R. B.; Balasubramanian, S. V.; Straubinger, R. M. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharm. Sci. 2001, 90, 1091–1105.
Mu, L.; Feng, S. S. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J. Control. Release 2001, 76, 239–254.
Lee, I. H.; Park, Y. T.; Roh, K.; Chung, H.; Kwon, I. C.; Jeong, S. Y. Stable paclitaxel formulations in oily contrast medium. J. Control. Release 2005, 102, 415–425.
Straubinger, R. M.; Sharma, A.; Murray, M.; Mayhew, E. Novel taxol formulations: Taxol-containing liposomes. J. Natl. Cancer Inst. Monogr. 1993, 69–78.
Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf. 2007, 6, 609–621.
Engels, F. K.; Mathot, R. A. A.; Verweij, J. Alternative drug formulations of docetaxel: A review. Anti-Cancer Drugs 2007, 18, 95–103.
Nightingale, G.; Ryu, J. Cabazitaxel (jevtana): A novel agent for metastatic castration-resistant prostate cancer. P. T. 2012, 37, 440–448.
Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37, 1590–1598.
Sofias, A. M.; Dunne, M.; Storm, G.; Allen, C. The battle of "nano" paclitaxel. Adv. Drug Deliv. Rev. 2017, 122, 20–30.
Carretta, R. M.; Eisenhauer, E.; Rozencweig, M. Methods for administration of taxol. U.S. Patents 5, 641, 803 A, June 24, 1997.
Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794–7803.
Tamura, T.; Sasaki, Y.; Nishiwaki, Y.; Saijo, N. Phase Ⅰ study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities. Jpn. J. Cancer Res. 1995, 86, 1203–1209.
Gotardo, M. A.; Monteiro, M. Migration of diethylhexyl phthalate from PVC bags into intravenous cyclosporine solutions. J. Pharm. Biomed. Anal. 2005, 38, 709–713.
Venkataramanan, R.; Burckart, G. J.; Ptachcinski, R. J.; Blaha, R.; Logue, L. W.; Bahnson, A.; Giam, C. S.; Brady, J. E. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am. J. Hosp. Pharm. 1986, 43, 2800–2802.
van Tellingen, O.; Beijnen, J. H.; Verweij, J.; Scherrenburg, E. J.; Nooijen, W. J.; Sparreboom, A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res. 1999, 5, 2918–2924.
Sparreboom, A.; Verweij, J.; Van der Burg, M. E.; Loos, W. J.; Brouwer, E.; Viganò, L.; Locatelli, A.; de Vos, A. I.; Nooter, K.; Stoter, G. et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer. Res. 1998, 4, 1937–1942.
Nannan Panday, V. R.; Huizing, M. T.; van Tellingen, O.; Hakvoort, R. A.; Willemse, P. H. B.; de Graeff, A.; Vermorken, J. B.; Beijnen, J. H. Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel. J. Oncol. Pharm. Pract. 1999, 5, 83–86.
Gelderblom, H.; Verweij, J.; Brouwer, E.; Pillay, M.; de Bruijn, P.; Nooter, K.; Stoter, G.; Sparreboom, A. Disposition of[G-3H] paclitaxel and Cremophor EL in a patient with severely impaired renal function. Drug Metab. Dispos. 1999, 27, 1300–1305.
Szebeni, J.; Alving, C. R.; Muggia, F. M. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J. Natl. Cancer Inst. 1998, 90, 300–306.
Dye, D.; Watkins, J. Suspected anaphylactic reaction to Cremophor EL. Br. Med. J. 1980, 280, 1353.
Weiss, R. B.; Donehower, R. C.; Wiernik, P. H.; Ohnuma, T.; Gralla, R. J.; Trump, D. L.; Baker, J. R., Jr.; Van Echo, D. A.; Von Hoff, D. D.; Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8, 1263–1268.
Szebeni, J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005, 216, 106–121.
van Zuylen, L.; Gianni, L.; Verweij, J.; Mross, K.; Brouwer, E.; Loos, W. J.; Sparreboom, A. Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 2000, 11, 331–337.
van Zuylen, L.; Verweij, J.; Sparreboom, A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 2001, 19, 125–141.
Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W. J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. Cancer Res. 1999, 59, 1454–1457.
Kongshaug, M.; Cheng, L. S.; Moan, J.; Rimington, C. Interaction of Cremophor EL with human plasma. Int. J. Biochem. 1991, 23, 473–478.
Sykes, E.; Woodburn, K.; Decker, D.; Kessel, D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer 1994, 70, 401–404.
Expósito, O.; Bonfill, M.; Moyano, E.; Onrubia, M.; Mirjalili, M. H.; Cusido, R. M.; Palazon, J. Biotechnological production of taxol and related taxoids: Current state and prospects. Anti-Cancer Agents Med. Chem. 2009, 9, 109–121.
Vasey, P. A.; Jayson, G. C.; Gordon, A.; Gabra, H.; Coleman, R.; Atkinson, R.; Parkin, D.; Paul, J.; Hay, A.; Kaye, S. B. Phase Ⅲ randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2004, 96, 1682–1691.
Fossella, F. V.; DeVore, R.; Kerr, R. N.; Crawford, J.; Natale, R. R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J. S.; Moore, M. et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 2000, 18, 2354–2362.
Webster, L. K.; Linsenmeyer, M. E.; Rischin, D.; Urch, M. E.; Woodcock, D. M.; Millward, M. J. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother. Pharmacol. 1997, 39, 557–560.
Eisenhauer, E. A.; Trudeau, M. An overview of phase Ⅱ studies of docetaxel in patients with metastatic breast cancer. Eur. J. Cancer 1995, 31, S11–S13.
Green, M. R.; Manikhas, G. M.; Orlov, S.; Afanasyev, B.; Makhson, A. M.; Bhar, P.; Hawkins, M. J. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17, 1263–1268.
Desai, N.; Trieu, V.; Damascelli, B.; Soon-Shiong, P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2, 59–64.
Gradishar, W. J.; Krasnojon, D.; Cheporov, S.; Makhson, A. N.; Manikhas, G. M.; Clawson, A.; Bhar, P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 2009, 27, 3611–3619.
Garlick, R. L.; Mazer, J. S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J. Biol. Chem. 1983, 258, 6142–6146.
Ait-Oudhia, S.; Straubinger, R. M.; Mager, D. E. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm. Res. 2012, 29, 2833–2844.
Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387–6392.
Hawkins, M. J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60, 876–885.
Sage, H.; Johnson, C.; Bornstein, P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. 1984, 259, 3993–4007.
Porter, P. L.; Sage, E. H.; Lane, T. F.; Funk, S. E.; Gown, A. M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 1995, 43, 791–800.
Neesse, A.; Frese, K. K.; Chan, D. S.; Bapiro, T. E.; Howat, W. J.; Richards, F. M.; Ellenrieder, V.; Jodrell, D. I.; Tuveson, D. A. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014, 63, 974–983.
Li, R.; Zheng, K.; Yuan, C.; Chen, Z.; Huang, M. D. Be active or not: The relative contribution of active and passive tumor targeting of nanomaterials. Nanotheranostics 2017, 1, 346–357.
Kim, T. Y.; Kim, D. W.; Chung, J. Y.; Shin, S. G.; Kim, S. C.; Heo, D. S.; Kim, N. K.; Bang, Y. J. Phase Ⅰ and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer. Res. 2004, 10, 3708–3716.
Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Multicenter phase Ⅱ trial of Genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2007, 18, 2009–2014.
Ventola, C. L. Progress in nanomedicine: Approved and investigational nanodrugs. P. T. 2017, 42, 742–755.
Kato, K.; Chin, K.; Yoshikawa, T.; Yamaguchi, K.; Tsuji, Y.; Esaki, T.; Sakai, K.; Kimura, M.; Hamaguchi, T.; Shimada, Y. et al. Phase Ⅱ study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 2012, 30, 1621–1627.
Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K. et al. A phase Ⅰ and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 2007, 97, 170–176.
van der Meel, R.; Lammers, T.; Hennink, W. E. Cancer nanomedicines: Oversold or underappreciated? Expert Opin. Drug Deliv. 2017, 14, 1–5.
Jain, M. M.; Gupte, S. U.; Patil, S. G.; Pathak, A. B.; Deshmukh, C. D.; Bhatt, N.; Haritha, C.; Babu, K. G.; Bondarde, S. A.; Digumarti, R. et al. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: A multicenter, randomized, comparative phase Ⅱ/Ⅲ study. Breast Cancer Res. Treat. 2016, 156, 125–134.
Stylianopoulos, T.; Jain, R. K. Design considerations for nanotherapeutics in oncology. Nanomed. Nanotechnol. Biol. Med. 2015, 11, 1893–1907.
Pattni, B. S.; Chupin, V. V.; Torchilin, V. P. New developments in liposomal drug delivery. Chem. Rev. 2015, 115, 10938–10966.
Koudelka, Š.; Turánek, J. Liposomal paclitaxel formulations. J. Control. Release 2012, 163, 322–334.
Zhang, Q.; Huang, X. E.; Gao, L. L. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed. Pharmacother. 2009, 63, 603–607.
Ye, L.; He, J.; Hu, Z. P.; Dong, Q. J.; Wang, H. B.; Fu, F. H.; Tian, J. W. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. Food Chem. Toxicol. 2013, 52, 200–206.
ClinicalTrials. gov. Pharmacokinetics Study of Liposomal Paclitaxel in Humans (LPSPK-H)[Online]. https://www.clinicaltrials.gov/ct2/show/NCT00606515 (accessed Mar 23, 2018).
Wang, X. H.; Zhou, J. C.; Wang, Y. S.; Zhu, Z. Y.; Lu, Y.; Wei, Y. Q.; Chen, L. J. A phase Ⅰ clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur. J. Cancer 2010, 46, 1474–1480.
Fan, Y. C.; Zhang, Q. Development of liposomal formulations: From concept to clinical investigations. Asian J. Pharm. Sci. 2013, 8, 81–87.
Zhang, J. A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 2005, 59, 177–187.
Fetterly, G. J.; Grasela, T. H.; Sherman, J. W.; Dul, J. L.; Grahn, A.; Lecomte, D.; Fiedler-Kelly, J.; Damjanov, N.; Fishman, M.; Kane, M. P. et al. Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during phase Ⅰ development of liposome-entrapped paclitaxel. Clin. Cancer Res. 2008, 14, 5856–5863.
Slingerland, M.; Guchelaar, H. J.; Rosing, H.; Scheulen, M. E.; van Warmerdam, L. J. C.; Beijnen, J. H.; Gelderblom, H. Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: A randomized, two-period crossover study in patients with advanced cancer. Clin. Ther. 2013, 35, 1946–1954.
Fasol, U.; Frost, A.; Büchert, M.; Arends, J.; Fiedler, U.; Scharr, D.; Scheuenpflug, J.; Mross, K. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann. Oncol. 2012, 23, 1030–1036.
Eichhorn, M. E.; Ischenko, I.; Luedemann, S.; Strieth, S.; Papyan, A.; Werner, A.; Bohnenkamp, H.; Guenzi, E.; Preissler, G.; Michaelis, U. et al. Vascular targeting by EndoTAGTM-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer 2010, 126, 1235–1245.
Bode, C.; Trojan, L.; Weiss, C.; Kraenzlin, B.; Michaelis, U.; Teifel, M.; Alken, P.; Michel, M. S. Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer. Oncol. Rep. 2009, 22, 321–326.
Thurston, G.; McLean, J. W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T. J.; Hanahan, D.; McDonald, D. M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 1998, 101, 1401–1413.
Luo, D. D.; Geng, J. M.; Li, N. S.; Carter, K. A.; Shao, S.; Atilla-Gokcumen, G. E.; Lovell, J. F. Vessel-targeted chemophototherapy with cationic porphyrin-phospholipid liposomes. Mol. Cancer Ther. 2017, 16, 2452–2461.
Löhr, J. M.; Haas, S. L.; Bechstein, W. O.; Bodoky, G.; Cwiertka, K.; Fischbach, W.; Fölsch, U. R.; Jäger, D.; Osinsky, D.; Prausova, J. et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase Ⅱ trial. Ann. Oncol. 2012, 23, 1214–1222.
Lee, I. H.; Hong, J. W.; Jang, Y.; Park, Y. T.; Chung, H. Development, optimization and absorption mechanism of DHP107, oral paclitaxel formulation for single-agent anticancer therapy. In New Advances in the Basic and Clinical Gastroenterology; Brzozowski, T., Ed.; INTECH Open Access Publisher, 2012; pp 357–374.
Hong, J. W.; Lee, I. H.; Kwak, Y. H.; Park, Y. T.; Sung, H. C.; Kwon, I. C.; Chung, H. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol. Cancer Ther. 2007, 6, 3239–3247.
Hong, Y. S.; Kim, K. P.; Lim, H. S.; Bae, K. S.; Ryu, M. H.; Lee, J. L.; Chang, H. M.; Kang, Y. K.; Kim, H.; Kim, T. W. A phase Ⅰ study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Invest. New Drugs 2013, 31, 616–622.
Kang, Y. K.; Ryu, M. H.; Park, S. H.; Park, S. R.; Kim, J. G.; Kim, J. W.; Cho, S. H.; Park, Y. I.; Rha, S. Y.; Kang, M. J. Efficacy and safety findings from DREAM: A phase Ⅲ study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy. Am. Soc. Clin. Oncol. 2016, 34, 4016.
Sparreboom, A.; Van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 1997, 94, 2031–2035.
Paek, I. B.; Ji, H. Y.; Lee, G. S.; Lee, H. S. Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J. Sep. Sci. 2006, 29, 628–634.
Lee, K. W.; Lee, K. H.; Zang, D. Y.; Park, Y. I.; Shin, D. B.; Kim, J. W.; Im, S. A.; Koh, S. A.; Yu, K. S.; Cho, J. Y. et al. Phase Ⅰ/Ⅱ study of weekly oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer. Oncologist 2015, 20, 896–897.
Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255–270.
Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49, 7253–7269.
Terwogt, J. M. M.; ten Bokkel Huinink, W. W.; Schellens, J. H. M.; Schot, M.; Mandjes, I. A. M.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase Ⅰ clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12, 315–323.
Fracasso, P. M.; Picus, J.; Wildi, J. D.; Goodner, S. A.; Creekmore, A. N.; Gao, F.; Govindan, R.; Ellis, M. J.; Tan, B. R.; Linette, G. P. et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies. Cancer Chemother. Pharmacol. 2009, 63, 451–458.
Homsi, J.; Bedikian, A. Y.; Papadopoulos, N. E.; Kim, K. B.; Hwu, W. J.; Mahoney, S. L.; Hwu, P. Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010, 20, 507–510.
Jones, R. J.; Hawkins, R. E.; Eatock, M. M.; Ferry, D. R.; Eskens, F. A. L. M.; Wilke, H.; Evans, T. J. J. A phase Ⅱ open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother. Pharmacol. 2008, 61, 435–441.
Luo, D. D.; Carter, K. A.; Lovell, J. F. Nanomedical engineering: Shaping future nanomedicines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7, 169–188.
Adams, M. L.; Lavasanifar, A.; Kwon, G. S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92, 1343–1355.
Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjugate Chem. 2010, 21, 797–802.
Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. M. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 2007, 24, 1029–1046.
Gaucher, G.; Dufresne, M. H.; Sant, V. P.; Kang, N.; Maysinger, D.; Leroux, J. C. Block copolymer micelles: Preparation, characterization and application in drug delivery. J. Control. Release 2005, 109, 169–188.
Li, J.; Stayshich, R. M.; Meyer, T. Y. Exploiting sequence to control the hydrolysis behavior of biodegradable PLGA copolymers. J. Am. Chem. Soc. 2011, 133, 6910–6913.
Makadia, H. K.; Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3, 1377–1397.
Kedar, U.; Phutane, P.; Shidhaye, S.; Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed. Nanotechnol. Biol. Med. 2010, 6, 714–729.
Kumari, A.; Yadav, S. K.; Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B: Biointerfaces 2010, 75, 1–18.
Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21, 2475–2490.
Esmaeili, F.; Ghahremani, M. H.; Esmaeili, B.; Khoshayand, M. R.; Atyabi, F.; Dinarvand, R. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349, 249–255.
Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J. F. W.; Hennink, W. E. Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release. Pharm. Res. 2010, 27, 2569–2589.
Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12, 6243s–6249s.
Gdowski, A. S.; Ranjan, A.; Sarker, M. R.; Vishwanatha, J. K. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine 2017, 12, 2083–2095.
Zhang, Z.; Xiong, X. Q.; Wan, J. L.; Xiao, L.; Gan, L.; Feng, Y. M.; Xu, H. B.; Yang, X. L. Cellular uptake and intracellular trafficking of PEG-b-PLA polymeric micelles. Biomaterials 2012, 33, 7233–7240.
Han, X. X.; Chen, D.; Sun, J.; Zhou, J. S.; Li, D.; Gong, F. R.; Shen, Y. L. A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time. J. Biomater. Sci., Polym. Ed. 2016, 27, 626–642.
Zhuang, B.; Du, L.; Xu, H. X.; Xu, X. L.; Wang, C.; Fan, Y. F.; Cong, M. Y.; Yin, J. Q.; Li, H. X.; Guan, H. S. Self-assembled micelle loading cabazitaxel for therapy of lung cancer. Int. J. Pharm. 2016, 499, 146–155.
Mahdaviani, P.; Bahadorikhalili, S.; Navaei-Nigjeh, M.; Vafaei, S. Y.; Esfandyari-Manesh, M.; Abdolghaffari, A. H.; Daman, Z.; Atyabi, F.; Ghahremani, M. H.; Amini, M. et al. Peptide functionalized poly ethylene glycol-poly caprolactone nanomicelles for specific cabazitaxel delivery to metastatic breast cancer cells. Mater. Sci. Eng. C 2017, 80, 301–312.
Herold, D. A.; Keil, K.; Bruns, D. E. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem. Pharmacol. 1989, 38, 73–76.
Garay, R. P.; Labaune, J. P. Immunogenicity of polyethylene glycol (PEG). Open Conf. Proc. J. 2011, 2, 104–107.
Cheng, T. L.; Wu, P. Y.; Wu, M. F.; Chern, J. W.; Roffler, S. R. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjugate Chem. 1999, 10, 520–528.
Yang, Q.; Wang, K.; Nie, J. J.; Du, B. Y.; Tang, G. P. Poly(N-vinylpyrrolidinone) microgels: Preparation, biocompatibility, and potential application as drug carriers. Biomacromolecules 2014, 15, 2285–2293.
Bailly, N.; Thomas, M.; Klumperman, B. Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate) as a drug delivery vehicle for hydrophobic drugs. Biomacromolecules 2012, 13, 4109–4117.
Zhu, Z. S.; Li, Y.; Li, X. L.; Li, R. T.; Jia, Z. J.; Liu, B. R.; Guo, W. H.; Wu, W.; Jiang, X. Q. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone) nanoparticles: Preparation and antitumor activity in vivo. J. Control. Release 2010, 142, 438–446.
Xie, C.; Zhang, P.; Zhang, Z. K.; Yang, C. C.; Zhang, J. L.; Wu, W.; Jiang, X. Q. Drug-loaded pseudo-block copolymer micelles with a multi-armed star polymer as the micellar exterior. Nanoscale 2015, 7, 12572–12580.
Aydin, O.; Youssef, I.; Yuksel Durmaz, Y.; Tiruchinapally, G.; ElSayed, M. E. H. Formulation of acid-sensitive micelles for delivery of cabazitaxel into prostate cancer cells. Mol. Pharm. 2016, 13, 1413–1429.
Weiszhár, Z.; Czúcz, J.; Révész, C.; Rosivall, L.; Szebeni, J.; Rozsnyay, Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci. 2012, 45, 492–498.
Zhang, Y. M.; Song, W. T.; Geng, J. M.; Chitgupi, U.; Unsal, H.; Federizon, J.; Rzayev, J.; Sukumaran, D. K.; Alexandridis, P.; Lovell, J. F. Therapeutic surfactant-stripped frozen micelles. Nat. Commun. 2016, 7, 11649.
Zhang, Y. M.; Wang, D. P.; Goel, S.; Sun, B. Y.; Chitgupi, U.; Geng, J. M.; Sun, H. Y.; Barnhart, T. E.; Cai, W. B.; Xia, J. et al. Surfactant-stripped frozen pheophytin micelles for multimodal gut imaging. Adv. Mater. 2016, 28, 8524– 8530.
Torchilin, V. P. Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 2007, 24, 1.
Shao, Y. J.; Zhang, C. G.; Yao, Q.; Wang, Y. Q.; Tian, B.; Tang, X.; Wang, Y. J. Improving cabazitaxel chemical stability in parenteral lipid emulsions using cholesterol. Eur. J. Pharm. Sci. 2014, 52, 1–11.
Ananias, H. J. K.; De Jong, I. J.; Dierckx, R. A.; van de Wiele, C.; Helfrich, W.; Elsinga, P. H. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr. Pharm. Des. 2008, 14, 3033–3047.
Safavy, A.; Khazaeli, M. B.; Qin, H. Y.; Buchsbaum, D. J. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer 1997, 80, 2354–2359.
Kulhari, H.; Pooja, D.; Shrivastava, S.; V.G. M, N.; Sistla, R. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf. B: Biointerfaces 2014, 117, 166–173.
Chen, W. J.; Guo, M.; Wang, S. L. Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system. Drug Dev. Ind. Pharm. 2016, 42, 1968–1976.
Song, Y.; Tian, Q.; Huang, Z.; Fan, D.; She, Z.; Liu, X.; Cheng, X.; Yu, B.; Deng, Y. Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. Int. J. Nanomedicine 2014, 9, 2307–2317.
Shahgaldian, P.; Da Silva, E.; Coleman, A. W.; Rather, B.; Zaworotko, M. J. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): A detailed study of preparation and stability parameters. Int. J. Pharm. 2003, 253, 23–38.
Qi, J. P.; Lu, Y.; Wu, W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr. Drug Metab. 2012, 13, 418–428.
Zhu, C. J.; An, C. G. Enhanced antitumor activity of cabazitaxel targeting CD44+ receptor in breast cancer cell line via surface functionalized lipid nanocarriers. Trop. J. Pharm. Res. 2017, 16, 1383–1390.
Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132, 171–183.
Kratz, F. A clinical update of using albumin as a drug vehicle—A commentary. J. Control. Release 2014, 190, 331–336.
Qu, N.; Lee, R. J.; Sun, Y.; Cai, G.; Wang, J.; Wang, M.; Lu, J.; Meng, Q.; Teng, L.; Wang, D. et al. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer. Int. J. Nanomed. 2016, 11, 3451–3459.
Qu, N.; Sun, Y. T.; Xie, J.; Teng, L. S. Preparation and evaluation of in vitro self-assembling HSA nanoparticles for cabazitaxel. Anti-Cancer Agents Med. Chem. 2017, 17, 294–300.
Huang, H. Y.; Lovell, J. F. Advanced functional nanomaterials for theranostics. Adv. Funct. Mater. 2017, 27, 1603524.
Tai, X. W.; Wang, Y.; Zhang, L.; Yang, Y. T.; Shi, K. R.; Ruan, S. B.; Liu, Y. Y.; Gao, H. L.; Zhang, Z. R.; He, Q. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J. Drug Target. 2017, 25, 179–187.
Shafirstein, G.; Bäumler, W.; Hennings, L. J.; Siegel, E. R.; Friedman, R.; Moreno, M. A.; Webber, J.; Jackson, C.; Griffin, R. J. Indocyanine green enhanced near-infrared laser treatment of murine mammary carcinoma. Int. J. Cancer 2012, 130, 1208–1215.
Reza, A. T.; Nicoll, S. B. Characterization of novel photocrosslinked carboxymethylcellulose hydrogels for encapsulation of nucleus pulposus cells. Acta Biomater. 2010, 6, 179–186.
Toğrul, H.; Arslan, N. Production of carboxymethyl cellulose from sugar beet pulp cellulose and rheological behaviour of carboxymethyl cellulose. Carbohydr. Polym. 2003, 54, 73–82.
Hoang, B.; Ernsting, M. J.; Tang, W. H. S.; Bteich, J.; Undzys, E.; Kiyota, T.; Li, S. D. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer Lett. 2017, 410, 169–179.
Ernsting, M. J.; Murakami, M.; Undzys, E.; Aman, A.; Press, B.; Li, S. D. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J. Control. Release 2012, 162, 575–581.
Ernsting, M. J.; Tang, W. L.; MacCallum, N. W.; Li, S. D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33, 1445–1454.
Bteich, J.; McManus, S. A.; Ernsting, M. J.; Mohammed, M. Z.; Prud'homme, R. K.; Sokoll, K. K. Using flash nanoprecipitation to produce highly potent and stable cellax nanoparticles from amphiphilic polymers derived from carboxymethyl cellulose, polyethylene glycol, and cabazitaxel. Mol. Pharm. 2017, 14, 3998–4007.
Müller, R. H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161–177.
Kan, P.; Chen, Z. B.; Lee, C. J.; Chu, I. M. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J. Control. Release 1999, 58, 271–278.
Khoeeniha, M. K.; Esfandyari-Manesh, M.; Behrouz, H.; Amini, M.; Varnamkhasti, B. S.; Atyabi, F.; Dinarvand, R. Targeted delivery of cabazitaxel by conjugation to albumin-PEG-folate nanoparticles using a cysteine-acrylate linker and simple synthesis conditions. Curr. Drug Deliv. 2017, 14, 1120–1129.
Schacher, F. H.; Rupar, P. A.; Manners, I. Functional block copolymers: Nanostructured materials with emerging applications. Angew. Chem., Int. Ed. 2012, 51, 7898–7921.
Gu, F.; Zhang, L. F.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA 2008, 105, 2586–2591.
Bensaid, F.; Thillaye du Boullay, O.; Amgoune, A.; Pradel, C.; Harivardhan Reddy, L.; Didier, E.; Sablé, S.; Louit, G.; Bazile, D.; Bourissou, D. Y-shaped mPEG-PLA cabazitaxel conjugates: Well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core–corona nanoparticles. Biomacromolecules 2013, 14, 1189–1198.
Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 2008, 126, 187–204.
Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991–1003.
Miranda, D.; Lovell, J. F. Mechanisms of light-induced liposome permeabilization. Bioeng. Transl. Med. 2016, 1, 267–276.
Meng, F. H.; Hennink, W. E.; Zhong, Z. Y. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009, 30, 2180–2198.
Brülisauer, L.; Gauthier, M. A.; Leroux, J. C. Disulfide-containing parenteral delivery systems and their redox-biological fate. J. Control. Release 2014, 195, 147–154.
Han, X. X.; Gong, F. R.; Sun, J.; Li, Y. Q.; Liu, X. F.; Chen, D.; Liu, J. W.; Shen, Y. L. Glutathione-responsive core cross-linked micelles for controlled cabazitaxel delivery. J. Nanopart. Res. 2018, 20, 42.
Xue, P.; Liu, D.; Wang, J.; Zhang, N.; Zhou, J. H.; Li, L.; Guo, W. L.; Sun, M. C.; Han, X. F.; Wang, Y. J. Redox-sensitive citronellol–cabazitaxel conjugate: Maintained in vitro cytotoxicity and self-assembled as multifunctional nanomedicine. Bioconjugate Chem. 2016, 27, 1360–1372.
Engin, K.; Leeper, D. B.; Cater, J. R.; Thistlethwaite, A. J.; Tupchong, L.; McFarlane, J. D. Extracellular pH distribution in human tumours. Int. J. Hyperthermia 1995, 11, 211–216.
Van Sluis, R.; Bhujwalla, Z. M.; Raghunand, N.; Ballesteros, P.; Alvarez, J.; Cerdán, S.; Galons, J. P.; Gillies, R. J. In vivo imaging of extracellular pH using 1H MRSI. Magn. Reson. Med. 1999, 41, 743–750.
Ojugo, A. S. E.; McSheehy, P. M. J.; McIntyre, D. J. O.; McCoy, C.; Stubbs, M.; Leach, M. O.; Judson, I. R.; Griffiths, J. R. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: A comparison of exogenous 19F and 31P probes. NMR Biomed. 1999, 12, 495–504.
Parhizkar, E.; Ahmadi, F.; Daneshamouz, S.; Mohammadi-Samani, S.; Sakhteman, A.; Parhizgar, G. Synthesis and characterization of water-soluble conjugates of cabazitaxel hemiesters-dextran. Anticancer Agents Med. Chem. 2017, 17, 1555–1562.
Shao, Y. J.; Li, S.; Tian, B.; Su, L. L.; Zhang, C. G.; Wang, Y. Q.; Tang, X.; Wang, Y. Evaluation of the stability and pharmacokinetics of cabazitaxel-loaded intravenous lipid microspheres: Beneficial effect of cholesterol. Eur. J. Lipid Sci. Technol. 2015, 117, 460–470.
Zhou, G. M.; Jin, X. Y.; Zhu, P.; Yao, J.; Zhang, Y. X.; Teng, L. S.; Lee, R. J.; Zhang, X. M.; Hong, W. Human serum albumin nanoparticles as a novel delivery system for cabazitaxel. Anticancer Res. 2016, 36, 1649–1656.
